Objective To investigate the changes of T helper 9( Th9) cells,interleukin-9( IL-9),and related transcription factors in previously untreated patients with chronic hepatitis C,as well as their association with clinical indices. Methods A total of 29 previously untreated patients with chronic hepatitis C who attended Hainan Provincial People's Hospital from December 2018 to July 2019 were enrolled,and 15 healthy individuals were enrolled as healthy controls. The patients with chronic hepatitis C received sofosbuvir/velpatasvir antiviral therapy for 12 weeks,and then plasma and peripheral mononuclear cells( PBMCs) were isolated. Flow cytometry was used to measure the percentage of CD3+CD4+IL-9+Th9 cells in PBMCs; ELISA was used to measure the plasma level of IL-9; quantitative real-time PCR was used to measure the relative mRNA expression of IL-9 and the transcription factors PU. 1 and Foxo1 in PBMCs. The t-test or the paired t-test was used for comparison between two groups,and a Pearson correlation analysis was used to investigate correlation. Results Compared with the healthy controls,the previously untreated chronic hepatitis C patients had significantly lower percentage of peripheral Th9 cells( 0. 92% ± 0. 14% vs 1. 14% ± 0. 21%,t = 4. 31,P < 0. 001) and plasma IL-9 level( 248. 2 ± 66. 97 pg/ml vs 309. 02 ± 88. 48 pg/ml,t = 2. 63,P = 0. 012). The previously untreated chronic hepatitis C patients had significantly lower relative mRNA expression of IL-9 and PU. 1 than the healthy controls( t = 20. 67 and 23. 21,both P < 0. 001),while there was no significant difference in the relative mRNA expression of Foxo1 between the previously untreated chronic hepatitis C patients and the healthy controls( P > 0. 05). In the previously untreated chronic hepatitis C patients,the percentage of peripheral Th9 cells,IL-9 level,and mRNA expression of IL-9 and PU. 1 were negatively correlated with HCV RNA( r =-0. 46,-0. 38,-0. 52,and-0. 41,all P < 0. 05),but they were not correlated with the level of alanine aminotransferase( all P > 0. 05). Sofosbuvir/velpatasvir antiviral therapy achieved virologic response in 29 chronic hepatitis Cpatients,and the percentage of peripheral Th9 cells and the mRNA expression of PU. 1 after antiviral therapy were significantly higher than those at baseline( t = 2. 20 and 6. 52,both P < 0. 05),while there were no significant changes in the plasma level of IL-9 and the relative mRNA expression of IL-9 from baseline to after treatment( both P > 0. 05). Conclusion Chronic hepatitis C virus infection may suppress the activation of Th9 cells,suggesting that Th9 cells might be involved in the chronicity of hepatitis C virus infection.
[1] HE Y,DONG L,CAO Y,et al. IL-9 and Th9 cells in tumor immunity[J]. Adv Exp Med Biol,2020,1240:35-46.
|
[2] MALIK S,SADHU S,ELESELA S,et al. Transcription factor Foxo1 is essential for IL-9 induction in T helper cells[J]. Nat Commun,2017,8(1):815.
|
[3] ORLOVA-FINK N,CHOWDHURY FZ,SUN X,et al. Preferential susceptibility of Th9 and Th2 CD4+T cells to X4-tropic HIV-1 infection[J]. AIDS,2017,31(16):2211-2215.
|
[4] KAPLAN MH,HUFFORD MM,OLSON MR. The development and in vivo function of T helper 9 cells[J]. Nat Rev Immunol,2015,15(5):295-307.
|
[5] NEURATH MF,KAPLAN MH. Th9 cells in immunity and immunopathological diseases[J]. Semin Immunopathol,2017,39(1):1-4.
|
[6] TAPPE D,PREZ-GIRN JV,ZAMMARCHI L,et al. Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase[J]. Med Microbiol Immunol,2016,205(3):269-273.
|
[7] AZEVEDO R,de SOUSA JR,ARAUJO M,et al. In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus[J].Sci Rep,2018,8(1):1.
|
[8] GORENEC L,ZIDOVEC LEPEJ S,GRGIC I,et al. The comparison of Th1,Th2,Th9,Th17 and Th22 cytokine profiles in acute and chronic HIV-1 infection[J]. Microb Pathog,2016,97:125-130.
|
[9] CUI M,LV Y,LU J,et al. Decreased frequency of circulating Th9 cells in patients with chronic hepatitis B infection[J]. J Clin Lab Anal,2018,32(2):e22246.
|
[10] BUTTRICK TS,WANG W,YUNG C,et al. Foxo1 promotes Th9 cell differentiation and airway allergy[J]. Sci Rep,2018,8(1):818.
|
[11] MALIK S,AWASTHI A. Transcriptional control of Th9 cells:Role of Foxo1 in interleukin-9 induction[J]. Front Immunol,2018,9:995.
|
[12] CASEY JL,FELD JJ,MACPARLAND SA. Restoration of HCV-specific immune responses with antiviral therapy:A case for DAA treatment in acute HCV infection[J]. Cells,2019,8(4):317.
|
[13] SANTANGELO L,BORDONI V,MONTALDO C,et al. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties[J]. Liver Int,2018,38(10):1741-1750.
|
[14] GAO Y,LIANG ZJ,FU J. Influence of sofosbuvir-based antiviral therapy on the expression profile of cytokines and chemokines in patients with chronic hepatitis C[J]. J Clin Hepatol,2019,35(10):2200-2204.(in Chinese)高艺,梁志军,符健.以索磷布韦为基础的治疗方案对慢性丙型肝炎患者细胞因子/趋化因子表达谱的影响[J].临床肝胆病杂志,2019,35(10):2200-2204.
|
[15] YAN H,ZHANG X,LV Y. The effect of entecavir therapy on immune status in chronic hepatitis B patients[J]. Iran J Immunol,2019,16(1):84-91.
|